You are here
IMMUNOMEDICS, INC.
UEI: S4NHH3294XM6
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
Amount: $133,835.00DESCRIPTION (provided by applicant): Interferon-alpha-2 (IFNa2) is indicated for the therapy of a variety of hematopoietic and solid tumors. However, its therapeutic potential has not been fully reali ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Dock and Lock: Novel Protein Engineering
Amount: $887,626.00DESCRIPTION (provided by applicant): The objective of this Phase II application is the commercial development of CEA-ImmunoPET for breast cancer imaging. CEA-ImmunoPET is a two-component product syste ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
MAb-based targeted chemotherapy of lung cancer
Amount: $964,355.00DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. As existing therapies do not significantly increase surviva ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
An anti-CD74 MAb-drug conjugate for B-cell malignancies
Amount: $802,014.00DESCRIPTION (provided by applicant): The goal of this work is to develop an antibody-doxorubicin conjugate for the targeted therapy of B-cell cancers that express the CD74 antigen. The Phase II projec ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
Novel RNase-based Immunotoxin for CD74-positive B-cell Malignancies
Amount: $134,285.00DESCRIPTION (provided by applicant): This is an amended application of 1 R43 CA121468-01, which was originally submitted on July 29, 2005. Immunomedics, Inc. has developed a series of recombinant immu ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
MAb-based targeted chemotherapy of lung cancer
Amount: $114,334.00DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. Continued efforts with newer, more efficacious, therapies a ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Dock and Lock: novel protein engineering
Amount: $134,285.00DESCRIPTION (provided by applicant): The objective of this research is to develop a new generation of fusion proteins that can be used for improved imaging and therapy of cancer and other diseases by ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
F-18 FDG Peptides for Pretargeted PET Imaging of Pancrea
Amount: $134,285.00DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a me ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
An Anti-CD-74 MAb-drug Conjugate for B-Cell Malignancies
Amount: $134,285.00DESCRIPTION (provided by applicant): The objective of this work is to develop an antibody-drug conjugate that will be useful against B-cell malignancies that express the CD74 antigen. More specifical ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Tetravalent bispecific fusion antibody for immunotherapy
Amount: $134,285.00DESCRIPTION (provided by applicant): Immunotherapy based on a naked monoclonal antibody (mAb), such as rituximab, has emerged as a safe and effective modality for treatment of indolent and aggressive ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health
